Rocket Lab (RKLB) Stock Surges as SpaceX Alternative Gains Traction

Key Highlights

• RKLB advanced 3.2% during Monday’s session, peaking at $116.25 before closing at $113.65, with lighter-than-usual trading activity
• Peter Beck, the company’s CEO, emphasized that only two firms have achieved true scale in space launch operations, highlighting RKLB’s competitive standing
• Wall Street analysts maintain optimistic outlooks, with Deutsche Bank and TD Cowen establishing $120 targets; overall consensus points to Moderate Buy
• CIBC Asset Management expanded its holdings by 36.5%, contributing to institutional ownership reaching 71.78%
• Company insiders disposed of 485,515 shares totaling approximately $66.9M over the past quarter, predominantly for tax settlement on equity compensation

---

Rocket Lab (RKLB) posted a 3.2% gain during Monday’s trading session, briefly reaching $116.25 before concluding at $113.65. Trading volume registered approximately 45% below typical levels, with roughly 13.3 million shares changing hands.

Rocket Lab USA, Inc., RKLB

The equity’s 52-week trading range spans from $25.24 to $151.00, positioning the current price approximately 24% beneath its peak.

Monday’s advance occurred despite a relatively calm news environment, though several favorable developments have been accumulating.

CEO Peter Beck recently generated attention by asserting that only two enterprises have successfully achieved scale in space launch operations—a statement positioning Rocket Lab within an exclusive tier and capturing investor focus.

Additionally, RKLB is attracting increased attention as a substitute investment for accessing the space sector ahead of SpaceX’s expected public debut. For market participants seeking space industry exposure without awaiting SpaceX’s market entry, Rocket Lab represents the most apparent publicly available alternative currently.

Wall Street Targets Continue Upward Trajectory

Multiple investment firms have elevated their price projections in recent sessions. Deutsche Bank increased its target from $73 to $120 while maintaining a Buy rating. TD Cowen implemented an identical adjustment, moving from $90 to $120. Needham similarly raised its forecast from $95 to $120. New Street Research initiated coverage with a Buy recommendation and $150 objective.

Stifel Nicolaus established a $132 projection. The aggregate consensus indicates a Moderate Buy rating with an average target of $98.88, although numerous individual forecasts exceed that figure substantially.

BTIG sustained a Hold rating, while Zacks revised its assessment from Strong Buy to Hold in February. Clearly, analyst sentiment isn’t universally aligned.

Institutional Accumulation Persists

CIBC Asset Management expanded its stake by 36.5% during Q4, acquiring an additional 5,604 shares to reach a total position of 20,971 shares valued at approximately $1.46 million.

Vanguard expanded its holdings by 13.4% in Q4, currently maintaining over 47.4 million shares worth approximately $3.3 billion. Swiss National Bank boosted its position by 67.7% in Q3. Institutional stakeholders now control 71.78% of outstanding shares.

Regarding insider transactions, SVP Arjun Kampani divested 70,000 shares at $145.13 on May 27th, while insider Marvin Bradford Clevenger sold 15,549 shares at $142.57 on May 26th. Both transactions occurred under pre-established 10b5-1 trading plans designed to satisfy tax withholding requirements on vesting equity compensation.

During Q1, RKLB reported revenue of $200.35 million, surpassing the consensus forecast of $189.65 million. This represented a 63.4% year-over-year increase. EPS registered at -$0.07, matching analyst projections. Wall Street anticipates -$0.29 EPS for the complete fiscal year.

The stock maintains a market capitalization of $65.77 billion, exhibits a beta of 2.48, and carries a debt-to-equity ratio of merely 0.02.

The post Rocket Lab (RKLB) Stock Surges as SpaceX Alternative Gains Traction appeared first on Blockonomi.